Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple MyelomaJesús F. San Miguel, Hermann Einsele, Binod Dhakal et al.|New England Journal of Medicine|2023Cited by 719
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trialNathan Fowler, Catherine Thiéblemont, Peter A. Riedell et al.|Nature Medicine|2021Cited by 523
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple MyelomaVânia Hungria, María-Victoria Mateos, Paweł Robak et al.|New England Journal of Medicine|2024Cited by 162
Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1Silvia Ling, John Allen, Edwin Lau et al.|Haematologica|2011Cited by 129
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working GroupMeletios Α. Dimopoulos, Evangelos Terpos, Giampaolo Merlini et al.|The Lancet Oncology|2023Cited by 120